Considerations in device development for Plasma Derived Therapies

27 September 2022 13:50 - 14:25

  • What are Plasma Derived Therapies?
  • Why are Plasma Derived Therapies different from other modalities?
  • What strategies do we have to tackle high drug volumes and comprehensive administration systems?
  • Challenges of higher protein concentration
  • Strategies to maintain protein stability
  • Conclusions

Karthik Lavakumar, Head of Device Development, Plasma Derived Therapies, Takeda